14:00 EST Efficacy data from THIO 101 expected very soon, says MAIA CEO
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MAIA:
- MAIA Biotechnology gets Orphan Drug Designation in treatment of malignant glioma
- MAIA Biotechnology reports Q3 EPS (36c), consensus (38c)
- MAIA Biotechnology reports Phase 2 trial data from THIO program
- MAIA Biotechnology announces 49 patients dosed in THIO-101 trial
- MAIA Biotechnology says THIO showed highly potent anticancer activity in gliomas
